Form 4: Terns Pharmaceuticals Director David Fellows Acquires Stock Options in Lieu of Cash Retainer

Director David Fellows of Terns Pharmaceuticals acquired stock options in lieu of cash retainer fees, according to a recent SEC Form 4 filing.

Summary

• David Fellows, a director at Terns Pharmaceuticals, acquired 8,183 stock options on July 1, 2024.
• The options were granted in lieu of a $35,000 cash retainer fee for the third and fourth quarters of 2024, as per the Issuer's Non-Employee Director Compensation Policy.
• The exercise price of the options is $6.85.
• The options vest monthly, with full vesting by January 1, 2025, and expire on June 30, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects standard compensation practices and insider confidence, but doesn't indicate any major strategic shifts or financial surprises.

Positives

• Director's confidence in the company is demonstrated by accepting stock options instead of cash.
• The vesting schedule incentivizes long-term commitment from the director.

Industry Context

This filing is a routine disclosure of insider transactions, common in the pharmaceutical industry where stock options are frequently used as part of director compensation packages.

Comparison to Industry Standards

• Director compensation packages in the pharmaceutical industry often include a mix of cash retainers and equity-based incentives like stock options.
• The vesting schedule and exercise price are typical for stock option grants to non-employee directors.
• Comparing the size of the option grant to those of directors at similar-sized biotech companies (e.g., Madrigal Pharmaceuticals, Viking Therapeutics) would provide further context.

Stakeholder Impact

• Shareholders may view the acceptance of stock options as a positive sign of director alignment with company performance.
• Employees may see this as a standard compensation practice for directors.

Key Dates